EVALUATION OF CLINICAL UTILITY OF DETECTING CIRCULATING TUMOR DNA MUTATION GENE LOCUS TP53 RS28934571 USING REAL TIME PCR AND DROPLET DIGITAL PCR IN EGYPTIAN HEPATOCELLULAR CARCINOMA PATIENTS
MAGHRABY, S., IBRAHIM, A., MONTASSER, I., HEFNY, Z., ABDELWAHED, M., MASSOUD, Y. (2023). EVALUATION OF CLINICAL UTILITY OF DETECTING CIRCULATING TUMOR DNA MUTATION GENE LOCUS TP53 RS28934571 USING REAL TIME PCR AND DROPLET DIGITAL PCR IN EGYPTIAN HEPATOCELLULAR CARCINOMA PATIENTS. EKB Journal Management System, 53(2), 227-232. doi: 10.21608/jesp.2023.312105
SAFEYA RAMADAN MAGHRABY; AMANY AHMAD IBRAHIM; IMAN MOHAMED FAWZY MONTASSER; ZEINAB MOHAMED HEFNY; MARWA ALI ABDELWAHED; YASMINE MAHMOUD MASSOUD. "EVALUATION OF CLINICAL UTILITY OF DETECTING CIRCULATING TUMOR DNA MUTATION GENE LOCUS TP53 RS28934571 USING REAL TIME PCR AND DROPLET DIGITAL PCR IN EGYPTIAN HEPATOCELLULAR CARCINOMA PATIENTS". EKB Journal Management System, 53, 2, 2023, 227-232. doi: 10.21608/jesp.2023.312105
MAGHRABY, S., IBRAHIM, A., MONTASSER, I., HEFNY, Z., ABDELWAHED, M., MASSOUD, Y. (2023). 'EVALUATION OF CLINICAL UTILITY OF DETECTING CIRCULATING TUMOR DNA MUTATION GENE LOCUS TP53 RS28934571 USING REAL TIME PCR AND DROPLET DIGITAL PCR IN EGYPTIAN HEPATOCELLULAR CARCINOMA PATIENTS', EKB Journal Management System, 53(2), pp. 227-232. doi: 10.21608/jesp.2023.312105
MAGHRABY, S., IBRAHIM, A., MONTASSER, I., HEFNY, Z., ABDELWAHED, M., MASSOUD, Y. EVALUATION OF CLINICAL UTILITY OF DETECTING CIRCULATING TUMOR DNA MUTATION GENE LOCUS TP53 RS28934571 USING REAL TIME PCR AND DROPLET DIGITAL PCR IN EGYPTIAN HEPATOCELLULAR CARCINOMA PATIENTS. EKB Journal Management System, 2023; 53(2): 227-232. doi: 10.21608/jesp.2023.312105

EVALUATION OF CLINICAL UTILITY OF DETECTING CIRCULATING TUMOR DNA MUTATION GENE LOCUS TP53 RS28934571 USING REAL TIME PCR AND DROPLET DIGITAL PCR IN EGYPTIAN HEPATOCELLULAR CARCINOMA PATIENTS

Journal of the Egyptian Society of Parasitology
Article 5, Volume 53, Issue 2, August 2023, Page 227-232  XML PDF (723.12 K)
DOI: 10.21608/jesp.2023.312105
View on SCiNiTO View on SCiNiTO
Authors
SAFEYA RAMADAN MAGHRABY; AMANY AHMAD IBRAHIM; IMAN MOHAMED FAWZY MONTASSER; ZEINAB MOHAMED HEFNY; MARWA ALI ABDELWAHED; YASMINE MAHMOUD MASSOUD
Department of Tropical Medicine, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt
Abstract
Liver cancer has been known to be the sixth cause of cancer worldwide. In Egypt, it is the
fourth cause of cancer and the second -related mortality. The P53 is considered the guardian of
the genome to prevent accumulation of oncogenic mutations that lead to malignant tumor.
The study compared the circulating tumor DNA (ctDNA) by targeting hotspot mutation gene
locus TP53 rs28934571 (c.747G>T) in normal persons, chronic liver disease patients, and in
hepatocellular carcinoma (HCC) ones to evaluate its diagnostic value and analyses the ctDNA
by targeting the hotspot mutation gene locus TP53 rs28934571 (c.747G>T).
The results showed that of 100 adults, G1: Eighty (80%) patients were diagnosed as HCC on
top of HCV, ten (10%) as HCV patients and ten (10%) healthy controls. All groups were matched
as to age and sex. The AST was increased in HCC patients as compared to healthy control
(P =0.018), forty patients (50%) were within Milan criteria, 12 patients (15%) within
USCF, 28 (35%) were beyond all of whom 39 (48.75%) patients were child A with mean
score of 12.45±5.94. Forty (50%) patients had one focal lesion, 16 patients had two focal lesions,
eight patients had four focal lesions and six patients had multiple lesions. The average
size of lesion in cm was (5.58±3.66). Among the HCC patients 38 (47.5%) patients developed
ascites, 35 (43.75%) patients developed PVT and 9 (11.25%) patients developed encephalopathy.
There was no significant difference in genetic typing between HCC patients, HCV ones
and healthy controls (p =0.622).
Keywords
Egyptian patients; HCC; TP53 mutation; Circulating-tumor DNA; Real time PCR
Statistics
Article View: 100
PDF Download: 108